Gossamer Bio Stock Market Value
| GOSS Stock | USD 0.37 -0.02 -5.13% |
| Symbol | Gossamer |
Earnings Share -0.75 | Revenue Per Share | Quarterly Revenue Growth 47.1% | Return On Assets | Return On Equity |
Book value captures Gossamer accounting equity, while market value captures the collective view of participants. Gossamer Bio's market capitalization is 87.68 M. A P/B ratio of 2.66 indicates the market values Gossamer Bio above its accounting book value. Enterprise value stands at 154.03 M. For Gossamer Bio, intrinsic value estimation helps reconcile what the market pays with what the books show.
Value and price for Gossamer Bio are related but not identical, and they can diverge across cycles. The quoted Gossamer Bio price is the exchange level where supply meets demand.
What-If Analysis
Historical what-if analysis for Gossamer Bio is useful because it converts abstract timing questions into a structured review of past performance under changing entry and holding periods. In practice, this review provides context for deciding whether Gossamer Bio's historical reward profile was stable enough to support the current thesis.
| 01/25/2026 |
| 04/25/2026 |
Starting with 0.00 in Gossamer Bio on January 25, 2026 and exiting today would produce 0.00 in aggregate gains. Overall, this is a 0.0% cumulative return in Gossamer Bio in aggregate over 90 days. Related stock peers for Gossamer Bio include Kalvista Pharmaceuticals, 4D Molecular, Olema Pharmaceuticals, Lexicon Pharmaceuticals, Rigel Pharmaceuticals, Prothena Plc, and Corvus Pharmaceuticals. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and comme... More
Upside and Downside Indicators for Gossamer Bio Summary
Gossamer Bio upside and downside signals reflect how the stock price has behaved relative to recent trading ranges. The signals capture how recent price action aligns with observed directional ranges.
| Information Ratio | -0.13 | |||
| Maximum Drawdown | 89.05 | |||
| Value At Risk | -9.52 | |||
| Potential Upside | 10.81 |
Gossamer Bio Market Risk Indicators Summary
The risk context for Gossamer Bio is expressed through volatility and drawdown-related metrics. These readings capture how return dispersion has evolved over measured periods.| Risk Adjusted Performance | -0.11 | |||
| Jensen Alpha | -1.51 | |||
| Total Risk Alpha | -1.49 | |||
| Treynor Ratio | 0.5698 |
The mean reversion principle applied to Gossamer Bio's suggests that neither prolonged outperformance nor underperformance is permanent. Identifying the root cause of Gossamer Bio's price dislocation is essential before acting on a mean reversion signal.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.11 | |||
| Market Risk Adjusted Performance | 0.5798 | |||
| Mean Deviation | 6.5 | |||
| Coefficient Of Variation | -796.50 | |||
| Standard Deviation | 11.9 | |||
| Variance | 141.67 | |||
| Information Ratio | -0.13 | |||
| Jensen Alpha | -1.51 | |||
| Total Risk Alpha | -1.49 | |||
| Treynor Ratio | 0.5698 | |||
| Maximum Drawdown | 89.05 | |||
| Value At Risk | -9.52 | |||
| Potential Upside | 10.81 | |||
| Skewness | -4.37 | |||
| Kurtosis | 29.75 |
Gossamer Bio Backtested Returns
Gossamer Bio posts a severely unstable volatility profile during the defined timeframe. It shows an Efficiency (Sharpe) Ratio of -0.13, quantifying negative return efficiency across 3 months. Signal processing identified twenty-four dispersion-based indicators. Please review metrics such as market risk-adjusted performance of 0.5798, risk-adjusted performance of -0.11, and standard deviation of 11.9 to examine volatility dispersion. The firm has a beta of -2.64, which conveys elevated sensitivity to broad market movements. Returns on Gossamer Bio are inversely related to market direction and amplified in magnitude, making it a counter-cyclical holding. At this point, Gossamer Bio has a negative expected return of -1.61%.
Auto-correlation | 0.02 |
Virtually no predictability
Gossamer Bio shows virtually no predictability when comparing price series from 25th of January 2026 to 11th of March 2026 against from 11th of March 2026 to 25th of April 2026. A strong serial relationship would imply that Gossamer Bio's recent trajectory contains information about its near-term direction. With a serial correlation of 0.02, only 2.0% of Gossamer Bio's price variation is attributable to patterns in preceding intervals.
| Correlation Coefficient | 0.02 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |